Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors

Related Experiment Video

Updated: Mar 21, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K

Ryan Gentzler1, Richard Hall1, Paul R Kunk1

  • 1Division of Hematology-Oncology, Department of Medicine, University of Virginia Health System, Charlottesville, VA, USA.

Immunotherapy
|May 4, 2016
PubMed

Insights

Immune checkpoint inhibitors targeting PD-1/PD-L1 blockade show promise beyond melanoma. This review explores their role in various cancers, focusing on the tumor immune microenvironment and PD-1/PD-L1 expression.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Immune checkpoint inhibitors (ICIs) are a breakthrough in melanoma treatment, particularly PD-1/PD-L1 blockade.
  • Their efficacy is being explored in numerous clinical trials across various malignancies.
  • Limited understanding exists regarding ICI efficacy in cancers beyond melanoma and lung cancer.

Purpose of the Study:

  • To review the tumor immune microenvironment in various cancers.
  • To examine the expression of PD-1/PD-L1 in different cancer types.
  • To discuss the effects of PD-1/PD-L1 inhibitors in modulating the immune response.

Main Methods:

  • Literature review focusing on immune checkpoint blockade in cancer.
  • Analysis of studies investigating PD-1/PD-L1 expression.
  • Examination of clinical trial data on PD-1/PD-L1 inhibitors.

Main Results:

  • Melanoma shows dramatic response to PD-1/PD-L1 blockade.
  • PD-1/PD-L1 blockade is being investigated in head and neck, prostate, urothelial, renal, breast, gastrointestinal, and lung cancers.
  • Understanding the tumor immune microenvironment is crucial for ICI efficacy.

Conclusions:

  • PD-1/PD-L1 inhibitors represent a promising therapeutic strategy for a wide range of cancers.
  • Further research is needed to optimize ICI therapy based on tumor immune microenvironment characteristics.
  • Immune modulation via PD-1/PD-L1 blockade holds significant potential in oncology.
Keywords:
PD-1PD-L1atezolizumabimmune checkpoint blockageimmune checkpoint inhibitorsimmunotherapynivolumabpembrolizumabsolid tumorstumor infiltrating lymphocytes

More Related Videos

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.8K
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

6.2K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.7K